<DOC>
	<DOC>NCT01272128</DOC>
	<brief_summary>The primary objective is to assess the quality of life of intramuscular (IM) Interferon Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) in a clinical practice setting.</brief_summary>
	<brief_title>Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Decision to treat with Interferon Beta1a (IFN beta1a) must precede enrollment, independently of the study and in compliance with the marketing authorization Study enrollment must occur prior to 4th weekly administration of IFN beta1a Able to understand and complete a selfadministered questionnaire No contraindications for IFN beta1a Key Subjects with history of hypersensitivity to natural or recombinant IFN beta or to any component Subjects with primary or secondary progressive MS Subjects with current severe depression and/or suicidal ideation Pregnant women Subjects participating in another clinical trial Subjects who do not want to participate in the study NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>